Levi & Korsinsky has launched an investigation into potential securities law violations by Phathom Pharmaceuticals after the company issued fiscal 2026 revenue guidance that fell short of Wall Street expectations. Phathom provided a revenue range with a high end of $325 million, below the analyst consensus of approximately $332 million to $334 million and $20 million below the high end of its previously issued $320 million to $345 million guidance range. The stock declined following the announcement, and the law firm is evaluating claims on behalf of shareholders who purchased PHAT stock and suffered losses. Investors are encouraged to submit their loss information for a free evaluation.
Phathom Pharmaceuticals IncRevenue guidance cut below expectations triggers investigation and stock decline.